m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05772
 [1]
m6A modification miR-515-5p miR-515-5p FTO Demethylation : m6A sites Direct Enhancement Non-coding RNA miR-515-5p TLR4  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
m6A Target hsa-miR-515-5p
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa-miR-515-5p microRNA View Details
Regulated Target Toll-like receptor 4 (TLR4) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary Overexpression of FTO alleviates osteoarthritis by regulating the processing of hsa-miR-515-5p and the Toll-like receptor 4 (TLR4)/MyD88/NF-kappaB axis
Responsed Disease Osteoarthritis ICD-11: FA05
 Disease Info 
Cell Process Cell apoptosis
In-vitro Model
 C-28/I2 Normal Homo sapiens CVCL_0187
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Toll-like receptor 4 (TLR4) 21 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name MPL-containing Pollinex allergy desensitization vaccine Preregistration [2]
Synonyms
Pollinex Quattro (ragweed allergy vaccine); Quattro MPL (ragweed allergy vaccine); MPL-containing Pollinex allergy desensitization vaccine (ragweed); Ragweed SC vaccine, Allergy Therapeutics/AllerPharma; MPL-containing Pollinex allergy desensitization vaccine (ragweed), AllergyTherapeutics/AllerPharma
    Click to Show/Hide
External Link
TTD: D08KNK
 Compound Name Resatorvid Phase 3 [3]
Synonyms
TAK-242; 243984-11-4; UNII-H2MZ648C31; CHEMBL225157; H2MZ648C31; TAK242; Resatorvid [INN]; TAK-242 (Resatorvid); C15H17ClFNO4S; SCHEMBL872197; GTPL9036; MolPort-035-773-739; BDBM50155929; ZINC13982410; 4003AH; AKOS027250774; CS-0408; KB-80786; AN-16512; HY-11109; A3850; W-5468; P111021; ethyl (6R)-6-[(2-chloro-4-fluorophenyl)sulfamoyl]cyclohexene-1-carboxylate; ethyl (6r)-6-[n-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate; ethyl (6R)-6-[(2-chloro-4-fluoro-phenyl)sulfamoyl]cyclohexene-1-carboxylate
    Click to Show/Hide
MOA Antagonist
Activity IC50 = 680 nM
External Link
CID: 11703255
TTD: D0E4GG
DrugBank: DB05943
 Compound Name ERITORAN Phase 3 [4]
Synonyms
UNII-551541VI0Y; E5564; CHEMBL501259; CHEBI:68609; 185955-34-4; 551541VI0Y; Eritoran [INN]; 3-O-decyl-2-deoxy-6-O-{2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11E)-octadec-11-enoylamino]-4-O-phosphonato-beta-D-glucopyranosyl}-2-[(3-oxotetradecanoyl)amino]-1-O-phosphono-alpha-D-glucopyranose; 3-O-Decyl-2-Deoxy-6-O-{2-Deoxy-3-O-[(3r)-3-Methoxydecyl]-6-O-Methyl-2-[(11z)-Octadec-11-Enoylamino]-4-O-Phosphono-Beta-D-Glucopyranosyl}-2-[(3-Oxotetradecanoyl)amino]-1-O-Phosphono-Alpha-D-Glucopyranose; B1287
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1.5 nM
External Link
CID: 6912404
TTD: D0SJ8Q
DrugBank: DB04933
 Compound Name Cadi-05 Phase 3 [5]
Synonyms
Mycobacterium w; Poly-TLR agonist polyantigenic vaccine (cancer), Cadila; Poly-toll-like receptor agonist polyantigenic vaccine (cancer), Cadila
    Click to Show/Hide
External Link
TTD: D0V0JR
 Compound Name G100 Phase 2 [6]
Synonyms
Caffeine, 8-((3-methoxypropyl)amino)-; 8-((3-Methoxypropyl)amino)caffeine; BRN 1086127; 95982-26-6; 8-(gamma-Methoxypropyl)-aminocoffein [German]; 8-(3-methoxypropylamino)-1,3,7-trimethylpurine-2,6-dione; 8-[(3-methoxypropyl)amino]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione; 8-(gamma-Methoxypropyl)-aminocoffein; AC1L1M3J; CTK5H8490; DTXSID70242056; MolPort-002-837-706; CCG-22657; ZINC17172964; AKOS001669223; MCULE-8333260193; LS-48594; EU-0014431; G-100; AO-343/41780992
    Click to Show/Hide
MOA Antagonist
External Link
CID: 56998
TTD: D0MD5M
 Compound Name NI-0101 Phase 1 [7]
Synonyms
TLR4 monoclonal antibody therapy (autoimmune and inflammatory diseases), Novimmune
    Click to Show/Hide
External Link
TTD: D04MZP
 Compound Name GSK1795091 Phase 1 [6]
MOA Agonist
External Link
TTD: D0MM4H
 Compound Name CRX-675 Phase 1 [7]
Synonyms
RC-529
    Click to Show/Hide
MOA Agonist
External Link
TTD: D0O2MO
 Compound Name OM-174 Phase 1 [8]
Synonyms
UNII-HC3530GGGG; HC3530GGGG; Defoslimod [INN]; OM 174 lipid; 2-Deoxy-6-o-(2-deoxy-2-((R)-3-hydroxytetradecanamido)-beta-D-glucopyranosyl)-2-((R)-3-hydroxytetradecanamido)-alpha-D-glucopyranose 1,6'-bis(dihydrogen phosphate) 2'(3)-laurate.; 2-Deoxy-6-O-(2-deoxy-2-((R)-3-hydroxytetradecanamido)-beta-D-glucopyranosyl)-2-((R)-3-hydroxytetradecanamido)-alpha-D-glucopyranose 1,6'-bis(dihydrogen phosphate) 2'(3)-laurate
    Click to Show/Hide
MOA Modulator
External Link
CID: 9833422
TTD: D09POQ
 Compound Name CS-4771 Discontinued in Phase 1 [9]
MOA Modulator
External Link
CID: 288
TTD: D09LZA
 Compound Name LZ-8 Terminated [7]
Synonyms
Lzip; FIP-gts; Ling Zhi-8; Protein adjuvant, Yeastern
    Click to Show/Hide
MOA Modulator
External Link
TTD: D06TTS
 Compound Name OM-294-DP Investigative [7]
MOA Modulator
External Link
TTD: D00GLW
 Compound Name OM-197-MP-AC Investigative [7]
MOA Modulator
External Link
TTD: D02SGT
 Compound Name CRX-526 Investigative [10]
Synonyms
UNII-8NLO017HHA; 8NLO017HHA; CHEMBL505526; BDBM50275658; 245515-64-4; Hexanoic acid, (1R)-1-(2-(((1S)-1-carboxy-2-((2-deoxy-3-O-((3R)-1-oxo-3-((1-oxohexyl)oxy)tetradecyl)-2-(((3R)-1-oxo-3-((1-oxohexyl)oxy)tetradecyl)amino)-4-O-phosphono-beta-D-glucopyranosyl)oxy)ethyl)amino)-2-oxoethyl)dodecyl ester; N-[(3R)-3-(Hexanoyloxy)myristoyl]-O-[2-[[(3R)-3-(hexanoyloxy)myristoyl]amino]-3-O-[(3R)-3-(hexanoyloxy)myristoyl]-4-O-phosphono-2-deoxy-beta-D-glucopyranosyl]-L-serine
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2.4 nM
External Link
CID: 24849153
TTD: D06MKE
 Compound Name 6-(2-aminophenoxy)benzo[d]isothiazol-3-amine Investigative [4]
Synonyms
CHEMBL458612; SCHEMBL14241034; ZINC3818486; BDBM50274720; AKOS022180470; AJ-45722
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3000 nM
External Link
CID: 44224215
TTD: D0J0GM
 Compound Name Fibronectin extra domain A Investigative [7]
Synonyms
Fibronectin extra domain A (vaccine adjuvant); Fibronectin extra domain A (vaccine adjuvant), Digna Biotech; TLR-4 antagonist (protein recombinant, vaccination), Digna Biotech/University of Navarra
    Click to Show/Hide
External Link
TTD: D0NB4V
 Compound Name AS04 Investigative [7]
MOA Modulator
External Link
TTD: D0Q7RV
 Compound Name 3-Hydroxy-Myristic Acid Investigative [11]
Synonyms
3-hydroxymyristate; 3-hydroxytetradecanoate; beta-hydroxymyristate; 3-hydroxy myristic acid; 3-hydroxytetradecanoate(1-)
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5288266
TTD: D0A0GD
DrugBank: DB02767
 Compound Name TriMixDC Investigative [12]
Synonyms
Dendritic cell vaccine (melanoma), Vrije Universiteit Brussel; TriMixDC (melanoma, intrademal), Universite Libre de Bruxelles
    Click to Show/Hide
External Link
TTD: D04PFD
 Compound Name Lauric Acid Investigative [11]
Synonyms
DODECANOIC ACID; 143-07-7; n-Dodecanoic acid; Dodecylic acid; Vulvic acid; Laurostearic acid; Dodecoic acid; Duodecylic acid; 1-Undecanecarboxylic acid; Aliphat No. 4; Neo-fat 12; C12 fatty acid; Ninol AA62 Extra; Wecoline 1295; Neo-fat 12-43; Hydrofol acid 1295; Hydrofol acid 1255; Duodecyclic acid; Hystrene 9512; Dodecylcarboxylate; Lauric acid (natural); Univol U-314; Lauric acid, pure; Coconut oil fatty acids; ABL; Undecane-1-carboxylic acid; Laurinsaeure; NSC-5026; CCRIS 669; C-1297; UNII-1160N9NU9U; n-Dodecanoate
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 3893
TTD: D0N0UC
DrugBank: DB03017
 Compound Name MYRISTIC ACID Investigative [13]
Synonyms
Tetradecanoic acid; 544-63-8; n-Tetradecanoic acid; n-Tetradecoic acid; Crodacid; n-Tetradecan-1-oic acid; 1-Tridecanecarboxylic acid; Univol U 316S; Hydrofol acid 1495; Emery 655; Myristinsaeure; Myristate; tetradecoic acid; Hystrene 9014; Neo-fat 14; Myristic acid (natural); C14 fatty acid; Myristic acid, pure; n-Myristic acid; Tetradecanoate; acide tetradecanoique; NSC 5028; FEMA No. 2764; CCRIS 4724; CH3-[CH2]12-COOH; HSDB 5686; UNII-0I3V7S25AW; Philacid 1400; CHEBI:28875; AI3-15381; Prifac 2942; C14:0; EINECS 208-875-2
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11005
TTD: D08OBF
DrugBank: DB08231
References
Ref 1 Overexpression of FTO alleviates osteoarthritis by regulating the processing of miR-515-5p and the TLR4/MyD88/NF-kappaB axis. Int Immunopharmacol. 2023 Jan;114:109524. doi: 10.1016/j.intimp.2022.109524. Epub 2022 Dec 18.
Ref 2 Allergy Therapeutics PLC. News Announcement. Allergy Therapeutics. Clinical Trials. Allergy Therapeutics PLC. 11 October 2006.
Ref 3 Clinical pipeline report, company report or official report of Takeda (2009).
Ref 4 Small molecule modulators of toll-like receptors. J Med Chem. 2008 Nov 13;51(21):6621-6.
Ref 5 Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
Ref 6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754).
Ref 8 Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172.
Ref 9 Eritoran insight for influenza treatment. SciBX 6(19); doi:10.1038/scibx.2013.453. May 16 2013
Ref 10 The 'Ethereal' nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5350-4.
Ref 11 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 12 Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int. 2013;2013:976383.
Ref 13 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. doi: 10.1093/nar/28.1.235.